However, the third-generation EGFR-TKI, osimertinib, is only reimbursed by the National Health Insurance (NHI) as a first-line treatment for advanced EGFR exon 19 deletion-positive NSCLC with central nervous system metastasis. Here, EGFR is linked to non-small cell lung carcinoma.